Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
0.6634
+0.0020 (0.30%)
May 27, 2025, 3:41 PM - Market open
Cue Biopharma Stock Forecast
Stock Price Forecast
According to 3 professional analysts, the 12-month price target for Cue Biopharma stock ranges from a low of $2.00 to a high of $4.00. The average analyst price target of $3.00 forecasts a 352.22% increase in the stock price over the next year.
Price Target: $3.00 (+352.22%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 2, 2025.
Analyst Ratings
The average analyst rating for Cue Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 1 | 1 |
Buy | 3 | 3 | 3 | 3 | 3 | 2 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 5 | 5 | 5 | 5 | 4 | 3 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $2 | Buy | Reiterates | $2 | +201.48% | Apr 2, 2025 |
Stifel | Stifel | Strong Buy Maintains $8 → $4 | Strong Buy | Maintains | $8 → $4 | +502.95% | Aug 20, 2024 |
JMP Securities | JMP Securities | Buy Maintains $15 → $2 | Buy | Maintains | $15 → $2 | +201.48% | Jul 26, 2024 |
Piper Sandler | Piper Sandler | Buy Maintains $8 → $3 | Buy | Maintains | $8 → $3 | +352.22% | Jul 26, 2024 |
Stifel | Stifel | Strong Buy Maintains $8 | Strong Buy | Maintains | $8 | +1,105.91% | Apr 9, 2024 |
Financial Forecast
Revenue This Year
5.98M
from 9.29M
Decreased by -35.65%
Revenue Next Year
7.53M
from 5.98M
Increased by 25.99%
EPS This Year
-0.58
from -0.72
EPS Next Year
-0.52
from -0.58
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 10.2M | 13.0M | 21.5M | ||
Avg | 6.0M | 7.5M | 16.9M | ||
Low | n/a | n/a | 12.7M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 10.3% | 117.2% | 185.9% | ||
Avg | -35.7% | 26.0% | 124.6% | ||
Low | - | - | 69.0% |
EPS Forecast
EPS | 2025 | 2026 | 2027 |
---|---|---|---|
High | -0.56 | -0.33 | -0.51 |
Avg | -0.58 | -0.52 | -0.50 |
Low | -0.62 | -0.65 | -0.49 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.